Carcinogenesis, Vol. 20, No. 3, 425-430,
March 1999
© 1999 Oxford University Press
Prevention by aspirin and its combination with 
-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon
Medical College of Ohio, Department of Pathology, 3000 Arlington Avenue, Toledo, OH 43614-5806 and
1 Chemoprevention Branch, Division of Cancer Prevention and Control, National Cancer Institute, Rockville, MD 20892, USA
The dose–response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels. Starting at either 7 or 22 weeks of age, the rats received aspirin. All rats received two doses of AOM (15 mg/kg each on days 7 and 14) and were killed on day 36. The lowest concentrations of aspirin to prevent ACF or reduce PGE2 levels were 600 and 400 mg/kg, respectively. To evaluate the prevention of tumors, rats received either 0 or 400 mg/kg aspirin for a total of 39 weeks with AOM (30 mg/kg) administered 7 days after the start of treatment. Aspirin had no effect on the yield of colon tumors. In a second experiment, rats started to receive 0, 200, 600 or 1800 mg/kg aspirin or 1000 mg/kg 
-difluoromethylornithine (DFMO) +/– aspirin. Eight and 15 days later, all the rats received 15 mg/kg AOM. Eleven weeks later, animals that were receiving the control diet started to receive 0, 200, 600 or 1800 mg/kg aspirin; 1000 or 3000 mg/kg DFMO; or 1000 mg/kg DFMO + 200 or 600 mg/kg aspirin. The animals were killed 32 weeks later. DFMO effectively reduced the yield of colon tumors when administered starting either before or after AOM while aspirin was much weaker. The combination of aspirin + DFMO administered after AOM was synergistic. Both aspirin and DFMO decreased the Mitotic Index, while apoptosis was increased only by DFMO. Our results demonstrated that aspirin and DFMO could prevent colon cancer when administered after AOM. Furthermore, aspirin reduced ACF, PGE2 levels and mitosis at concentrations that did not prevent cancer. In contrast, the ability to enhance apoptosis did correlate with the prevention of cancer.
Abbreviations: ACF, aberrant crypt foci; AOM, azoxymethane; COX, cyclooxygenase; DFMO, -difluoromethylornithine; EHRT, Environmental Health Research and Testing Inc; NSAID, non-steroidal anti-inflammatory drug; ODC, ornithine decarboxylase; PGE2, prostaglandin E2.
2 To whom correspondence should be addressed Email: mpereira{at}mco.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. W. Gerner and F. L. Meyskens Jr. Combination Chemoprevention for Colon Cancer Targeting Polyamine Synthesis and Inflammation Clin. Cancer Res., February 1, 2009; 15(3): 758 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. K. Glebov, L. M. Rodriguez, P. Soballe, J. DeNobile, J. Cliatt, K. Nakahara, and I. R. Kirsch Gene Expression Patterns Distinguish Colonoscopically Isolated Human Aberrant Crypt Foci from Normal Colonic Mucosa. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2253 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pereira, L. Tao, W. Wang, Y. Li, A. Umar, V. E. Steele, and R. A. Lubet Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-{alpha} gene in rat colon tumors Carcinogenesis, October 1, 2004; 25(10): 1917 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Shpitz, E Klein, G Buklan, D Neufeld, A Nissan, H R Freund, M Grankin, and J Bernheim Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer Gut, November 1, 2003; 52(11): 1598 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Herendeen and C. Lindley Use of NSAIDs for the Chemoprevention of Colorectal Cancer Ann. Pharmacother., November 1, 2003; 37(11): 1664 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dong, K. Guda, P. R. Nambiar, A. Rezaie, G. S. Belinsky, G. Lambeau, C. Giardina, and D. W. Rosenberg Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis Carcinogenesis, February 1, 2003; 24(2): 307 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R. A. Newman, R. A. Lubet, and C. S. Yang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and {alpha}-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis, December 1, 2002; 23(12): 2095 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sun, X. M. Tang, E. Half, M. T. Kuo, and F. A. Sinicrope Cyclooxygenase-2 Overexpression Reduces Apoptotic Susceptibility by Inhibiting the Cytochrome c-dependent Apoptotic Pathway in Human Colon Cancer Cells Cancer Res., November 1, 2002; 62(21): 6323 - 6328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tao, P. M. Kramer, W. Wang, S. Yang, R. A. Lubet, V. E. Steele, and M. A. Pereira Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents Carcinogenesis, September 1, 2002; 23(9): 1447 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Hawk, J. L. Viner, A. Dannenberg, and R. N. DuBois COX-2 in Cancer--A Player That's Defining the Rules J Natl Cancer Inst, April 17, 2002; 94(8): 545 - 546. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and W. Ki Hong Cancer Prevention by Delay : Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. Clin. Cancer Res., February 1, 2002; 8(2): 305 - 313. [Full Text] [PDF]
|
|
|
|
|
|
R. N. DuBois New paradigms for cancer prevention Carcinogenesis, May 1, 2001; 22(5): 691 - 692. [Full Text] [PDF]
|
|
|
|
|
|
L. Y. Y. Fong, V. T. Nguyen, A. E. Pegg, and P. N. Magee {{alpha}}-Difluoromethylornithine Induction of Apoptosis: A Mechanism Which Reverses Pre-established Cell Proliferation and Cancer Initiation in Esophageal Carcinogenesis in Zinc-deficient Rats Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 191 - 199. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Fischer, M. Lee, and R. A. Lubet Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice Carcinogenesis, January 1, 2001; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. and C. M. Higuchi Dietary Soy Protein Is Associated with Reduced Intestinal Mucosal Polyamine Concentration in Male Wistar Rats J. Nutr., July 1, 2000; 130(7): 1815 - 1820. [Abstract] [Full Text]
|
|
|
|
|
|
E. I. Salim, H. Wanibuchi, K. Morimura, S. Kim, Y. Yano, S. Yamamoto, and S. Fukushima Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine Carcinogenesis, February 1, 2000; 21(2): 195 - 203. [Abstract] [Full Text] [PDF]
|
|